Latest Breaking News On - Orphan drug designation - Page 2 : comparemela.com

Daewoong Pharmaceutical s Bersiporocin Receives Orphan Drug Designation In Europe To Treat Idiopathic Pulmonary Fibrosis

Daewoong Pharmaceutical s Bersiporocin Receives Orphan Drug Designation In Europe To Treat Idiopathic Pulmonary Fibrosis
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

South koreaSoult ukpyolsiEuropean medicines agencyEuropean molecular biology organizationClinical developmentKorea drug development fundOrphan drug designationBersiporocin receivesOrphan drug designationTreat idiopathic pulmonary fibrosisClinical development supportDaewoong pharmaceutical

Zydus Lifesciences launches trial for sclerosis treatment, shares up

Zydus Lifesciences launches trial for sclerosis treatment, shares up
thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.

Zydus lifesciences ltdAmyotrophic lateral sclerosisSecondary endpointsSlow vital capacityCryopyrin associated periodic syndromeOrphan drug designation

Zydus Receives Approval For ALS Phase II Trial Of ZYIL1

ZYIL1 is a novel oral small molecule NLRP3 inhibitor that is highly potent in human whole blood assay and can suppress inflammation caused by the NLRP3 inflammasome, , zydus, NLRP3 inhibitor, ZYIL1, Amyotrophic Lateral Sclerosis (ALS)

United kingdomUnited statesZydus lifesciencesPankajr patelClinical pharmacology in drug developmentCenters for diseaseEurope european unionCentral drugs standard control organisationAmyotrophic lateral sclerosisOrphan drug designationCryopyrin associated periodic syndromeUnited statesaDisease controlEuropean unionKey secondary endpointsSlow vital capacity

Lisata Up 9% On Securing EMA Orphan Drug Designation For LSTA1

Shares of Lisata Therapeutics, Inc. (LSTA) are up 9% on Tuesday after the company announced that it has been granted Orphan Medicine designation by the European Medicines Agency (EMA) Committee.

Lisata therapeutics incEuropean medicines agencyLisata therapeuticsOrphan medicineOrphan drug designationLisata therapeutics

Baudax Bio: FDA Grants Orphan Drug Designation To TI-168 For Hemophilia A With Inhibitors

Baudax Bio, Inc. (BXRX), a biotechnology company, announced Thursday that the U.S. Food and Drug Administration or FDA has granted orphan drug designation to its lead clinical candidate TI-168 for the treatment of Hemophilia A with inhibitors.

United statesGerri henwoodBaudax bioMore such health newsDrug administrationBaudax bio incChief executive officerInvestigational new drugClinical trialOrphan drug designationHemophilia aBaudax bioI 168